- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:
KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS AND MANUFACTURING EXPERIENCE AT EBMT 2023 Stockley Park, UK – 19 April 2023 – Kite, a Gilead Company, will support eight data presentations, including updated findings in multiple indications across its portfolio of two CAR T-c.
Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 CongressSub-analyses from Kite’s ZUMA-7 study of CAR T cell therapy in second-line diffuse large B cell lymphoma includes data in patients over 65 and by tumour burden characteristicsLonger-term d.
Kite, a Gilead Company, presents long-term CAR T cell therapy data in lymphomas at the 48th EBMT Annual Meeting Primary analysis of pivotal data on earlier use of CAR T cell therapy as second-line treatment in relapsed/refractory diffuse large B cell lymphomaLong-term overall survival and safety management data.